Trial Profile
ABSORB Everolimus-Eluting Bioresorbable Scaffold In Coronary Interventions: 12-Months Results Of a Single Center Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Apr 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Acute coronary syndromes; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2015 New trial record